The BPC-157 peptide

The BPC-157 peptide, in specification terms

The BPC-157 peptide is fifteen amino acids in a single unbranched chain: glycine, glutamate, proline, proline, proline, glycine, lysine, proline, alanine, aspartate, aspartate, alanine, glycine, leucine, valine. Written in single letters that is GEPPPGKPADDAGLV. The molecular formula is C62H98N16O22, the molecular weight 1419.53 g/mol, and the registry number CAS 137525-51-0. Fifteen residues makes it a pentadecapeptide, and that word and the abbreviation both turn up in the literature for the same molecule. Reading a sequence letter by letter, and counting residues off it, is the method set out in what is a peptide.

The sequence is written without a terminal modification. There is no N-terminal acetyl group and no C-terminal amide, so both ends of the chain are free. That is worth noting because short research peptides are often supplied N-acetylated, and an acetyl group is written into the sequence rather than left implied. The side-by-side in BPC-157 vs TB-500 sets out one such pair in full.

Physically the BPC-157 peptide is a white to off-white lyophilised cake, soluble in bacteriostatic water and in 0.9% sodium chloride, stored at −20°C for the long term and 2 to 8°C in use. In this catalogue BPC-157 ships as a 10mg vial released at 99.51% purity by HPLC, and it is a component of the GLOW and KLOW blends at 10mg each.

Those four figures, sequence, formula, mass and registry number, are worth stating together because almost nothing else states them together. Of the nine results measured on this search, one is a 2014 journal paper that gives the sequence and a rounded mass; the registry number appears on none of them. A specification is not a difficult thing to publish. It is simply that most pages written about this molecule are written about something other than the molecule.

Where the BPC-157 peptide name comes from, and the other names it answers to

BPC stands for Body Protection Compound. That name belongs to a protein identified in gastric juice, not to the fifteen-residue chain sold under the abbreviation. The peptide in the vial corresponds to a partial sequence of that protein: one region of it, lifted out and made on its own.

This matters more than it sounds. The fragment does not occur as a free peptide in nature. Nothing secretes GEPPPGKPADDAGLV; the region exists inside a larger molecule, and the fifteen-residue version exists because that region was the part of interest and synthesis was the way to isolate it. Every vial of the BPC-157 peptide anywhere is a laboratory construct with a borrowed sequence.

The 157 is a laboratory designation and nothing more. It is not a residue count and not a mass: the chain is fifteen residues and 1419.53 g/mol, and neither number is anywhere near 157. Both assumptions get made, which is the only reason it is worth saying out loud.

The literature's own name for the BPC-157 peptide is longer than the catalogue's. Papers in the field write "stable gastric pentadecapeptide BPC 157" in full, often in the title, and a 2025 narrative review in PubMed Central dates the first description of the fragment to Sikirić and colleagues in 1993. That phrase is the one to search on if the intention is to find primary literature rather than commentary, because it is the string the authors themselves use.

Then there are the codes. The United States Department of Defense's Operation Supplement Safety page lists Body protection compound 157, BPC15, PL10, PL14736 and Bepecin as other names for the same substance, and lists them without saying what any of them are. They are development codes and alternative spellings, not different molecules, and confusing them for analogues is an easy mistake to make when a supplier listing uses one and a paper uses another.

The one entry in that group that is genuinely a different preparation is arginate. "BPC-157 arginate" is the same fifteen residues with a different counter-ion, which is a salt-form question rather than a sequence question, and the next section is about exactly that.

The same distinction applies to the other fragment peptides in this category. TB-500, to take the one BPC-157 is most often set beside, corresponds to a region of the protein thymosin beta-4 rather than being that protein. Preclinical work on a parent protein does not automatically describe a fragment of it, and work on a fragment does not describe the parent. Where a paper names one, it means one, and an abbreviation is not a licence to read across. The page on what is TB-500 sets out the same problem from the other side.

Four prolines, three glycines and a pair of aspartates

Seven of the fifteen residues of the BPC-157 peptide are either proline or glycine. That is an unusual composition, and it is the reason this particular chain behaves less like a floppy short peptide than its length suggests.

Proline is the residue that constrains a backbone. Its side chain loops back and bonds to its own backbone nitrogen, which fixes one of the two rotatable angles at that position and removes the amide hydrogen that every other residue offers to hydrogen bonding. One proline stiffens a local stretch. Positions three, four and five here are three prolines in a row, with a fourth at position eight, and a run like that imposes a defined local geometry rather than leaving the chain to sample freely.

Glycine does the opposite. With a hydrogen atom for a side chain it is the most permissive residue there is, and the three glycines, at positions one, six and thirteen, sit around the proline runs. The chain alternates between constrained stretches and hinges, which is a specific shape problem rather than the near-random coil most fifteen-residue peptides present in solution.

Charge sits almost entirely on one side of the ledger. One lysine at position seven is the only basic side chain, against a glutamate at position two and the adjacent aspartate pair at positions ten and eleven. Three acidic side chains to one basic makes an acidic, strongly hydrophilic molecule, which is consistent with how readily the lyophilised cake takes up bacteriostatic water and saline.

There is a practical consequence to all of this, and it is not about shape. A proline-rich sequence is a harder sequence to build cleanly, and a harder sequence to build cleanly is one where the purity figure on the certificate is doing more work. That thread runs through the synthesis section below and out the other side into what the analysis can and cannot show.

Salt form, and why two vials marked 10mg are not the same mass of peptide

A vial labelled 10mg contains 10mg of fill. It does not contain 10mg of bare peptide, and the gap between those two statements is the single most misread thing in this category.

Purified peptide comes off preparative HPLC as a salt. The mobile phase is generally acidified with trifluoroacetic acid, the acidic groups on the chain pick up the counter-ion, and what is freeze-dried is the trifluoroacetate salt rather than the free peptide. The BPC-157 peptide has three acidic side chains and a free C-terminal carboxylate, which is a lot of sites for a counter-ion to sit on relative to a fifteen-residue chain. Add the water that a lyophilised cake holds even when dry to the touch, and the fill weight and the peptide weight are simply different quantities.

This is why net peptide content exists as a separate line on a certificate. It is the measured mass of peptide in the vial, stated in milligrams, after the counter-ion and the residual water have been accounted for. HPLC purity answers a different question, namely what fraction of the peptide present is the intended sequence, and a certificate that reports one without the other has answered half of it.

Some suppliers exchange the trifluoroacetate for acetate, and a few sell material described as free base or as an arginate. None of that changes the sequence, the formula or the 1419.53 g/mol. All of it changes the number of milligrams of peptide behind a given label weight. When one listing looks cheaper than another per milligram, the salt form and the net peptide content are the first two things to compare, and how to read a peptide certificate of analysis sets out where on the document to find them.

On the lots released here the measured content runs slightly above the label rather than below it: 10.68mg of peptide in a 10mg vial on the current lot. That is a fill tolerance, not a purity claim, and it is stated because it is measured. A supplier who publishes no content figure at all is not publishing a better one.

How a fifteen-residue chain is made

The BPC-157 peptide is made by solid-phase synthesis, the general route for a peptide of this length. The C-terminal valine is anchored to a resin bead and the chain is extended one residue at a time towards the N-terminus. The cycle is deprotect, couple, wash, repeat, with the growing peptide held on the bead throughout. One coupling step for every residue after the first.

Proline makes those steps more awkward than the residue count suggests. Its nitrogen is a secondary amine inside a ring, so coupling onto it is slower and more sterically hindered than coupling onto an ordinary residue, and consecutive prolines are a known difficult stretch in synthesis. An incomplete coupling leaves a chain missing one residue, which is a deletion sequence: a molecule close enough in mass and behaviour to the target to need separating out.

A deletion sequence is the impurity worth understanding, because it is the one that behaves most like the product. Drop a proline from GEPPPGKPADDAGLV and the result is fourteen residues, roughly 97 g/mol lighter, with almost the same charge, almost the same polarity and a retention time close enough to the target that a short or poorly resolved chromatographic method will not separate the two peaks. That is the whole argument for a long analytical gradient and a published chromatogram rather than a bare percentage.

That separation is preparative HPLC, generally with trifluoroacetic acid in the mobile phase, which is where the trifluoroacetate counter-ion in finished peptide material usually comes from. The purified peptide is then frozen and dried under vacuum, which is what produces a cake rather than a powder. The form, and the reason for it, is covered in what lyophilized powder is. The same HPLC method, run analytically, is what the purity figure on the certificate reports.

How BPC-157 peptide identity and purity are documented

Two measurements do the work, and they answer different questions. Mass spectrometry answers "is this the right molecule". Reverse-phase HPLC answers "how much of what is here is that molecule". Neither substitutes for the other, and a certificate that carries only one has told you half of what you needed.

Identity confirmation by LC-MS is the more absolute of the two. The instrument measures the mass of what elutes and compares it with the mass calculated from GEPPPGKPADDAGLV: 1419.53 g/mol for the neutral peptide, observed in practice as the charged ions the instrument actually sees. A match at that mass, on a chromatographic peak at the expected retention time, is what a certificate means by "identity confirmed". A mass a hundred daltons light is a deletion sequence; a mass offset by a counter-ion is a salt; an unexpected mass is a different peptide altogether, which is how substitution gets caught.

The HPLC figure is a purity figure, and it is an area percent: the fraction of the total detected peak area that belongs to the main peak, at a stated detection wavelength. It is a relative measurement, which is why the method matters as much as the number. A gradient too short to resolve a deletion sequence from the target will report a higher purity than a longer one on the same material, and both numbers will be honestly obtained. Peptide purity testing covers what a method has to do before its percentage means anything.

The certificates published here for the BPC-157 peptide name the laboratory, the lot, the accession number and a search code, alongside the appearance, the HPLC result, the identity result and the net peptide content. The accession number is the laboratory's own reference for the sample, and it is the field that makes a certificate checkable against the laboratory rather than only against the supplier who printed it. Lot 2FRBRG, to take the current one, carries accession 2605270306 from Freedom Diagnostics.

It is worth being equally clear about what these documents do not establish, because a release certificate is a narrow instrument and it is often read as a broad one.

What a certificate says about a given BPC-157 peptide lot

Purity is a property of a lot, not of a compound, so the only number worth anything is the one measured on the material that ships. The current lot is 2FRBRG: a 10mg vial, released on 30 May 2026 at 99.51% by HPLC, with a net peptide content of 10.68mg, assayed by Freedom Diagnostics. The lot before it, BPC11182025-J, was released on 30 April 2026 at 99.247% with a net peptide content of 10.65mg, and before that WQ988T, released on 11 March 2026 at 99.665% with 11.15mg. All three documents sit in the certificate of analysis library alongside every other lot released here.

Three lots, three different purity figures, three different content figures, one specification. That spread is the point rather than an embarrassment. 99.247%, 99.51% and 99.665% are three separate measurements on three separate syntheses, and the variation between them is what a real measurement looks like. A supplier quoting a single identical figure across every lot for years is quoting a specification, and the difference between the two is set out in what peptide purity means.

The HPLC percentage and the net peptide content answer different questions and are often confused. The HPLC figure says how much of the peptide present is the intended sequence rather than deletion sequences and other synthesis by-products. Net peptide content says how much actual peptide is in the vial, once the counter-ion and the water that a lyophilised cake carries are accounted for. That is why the figure is stated in milligrams against the vial size rather than as a percentage of it.

All three certificates come from Freedom Diagnostics, an independent laboratory rather than the synthesis house, and all three are published against the lot number printed on the vial. That is the check to make before an order, on any supplier: not whether a certificate exists somewhere on the site, but whether the one in front of you names the lot that will arrive. Typing a lot number into the batch verification page is the fastest way to establish that for a vial already in hand, and how to vet a research peptide supplier sets out the rest of the checks around it.

Where the BPC-157 peptide sits among related research peptides

Three molecules come up together in this corner of the catalogue, and they are routinely confused for one another because they are studied for overlapping things. They are not chemically similar in any respect that matters. Set their specifications side by side and the confusion does not survive it.

BPC-157 and TB-500 are both synthetic fragments of larger proteins, and that is the whole of their similarity: fifteen residues against seven, 1419.53 g/mol against 889.0, unrelated parent proteins, no shared subsequence, and a free N-terminus against an acetylated one. They are paired in the Repair Reference Panel because they are studied side by side in the literature, not because they are variants of a common theme. BPC-157 vs TB-500 takes the comparison residue by residue.

GHK-Cu is a different kind of thing again: three residues, a copper(II) ion held in the coordination site they form, and a tripeptide that does occur free in the body rather than only as a region of something bigger. It is the one molecule of the three whose defining property is inorganic chemistry, which the GHK-Cu copper peptide profile goes into properly.

Regulatory status, stated as fact

Four separate bodies have a published position on this substance, and none of them is a matter of interpretation. Stating them is not a warning and not a disclaimer; it is part of describing what the material is.

The United States Food and Drug Administration has not approved the BPC-157 peptide as a drug for any use. It sits in Category 2 of the agency's bulk drug substances lists, the category for substances with significant safety risks, which is the classification that keeps it out of the hands of compounding pharmacies as a bulk substance. An FDA advisory committee took the substance up again in July 2026 in connection with the Section 503A Bulks List; no final decision has been published, so the Category 2 classification is the one in force.

The World Anti-Doping Agency prohibits it at all times under class S0, non-approved substances, which is the class that covers any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. The United States Anti-Doping Agency follows the same list. Two of the nine pages ranking for this term exist substantially to say so.

None of that is a complication for a laboratory supplier; it is the reason the supply is framed the way it is. Material sold here is a reference standard for in-vitro and preclinical research, it is not sold for use in people or animals, and the regulatory position above is one of the reasons that boundary is drawn where it is rather than a footnote at the end of a page that argues otherwise.

What the regulatory record does bear on directly is product quality. The FDA's 2026 evidence and safety review of the substance raised impurities and inconsistent characterisation of the active ingredient in material found on the market. Those are exactly the two things a lot-matched, independently issued certificate is for: an identity confirmation against the calculated mass answers characterisation, and a published chromatogram with a stated method answers impurities. A page can call third-party testing non-negotiable, as one of the ranking pages does, and still give a reader no way to act on it. The way to act on it is to read the document for the lot in hand.

The acid-stability question, and what a certificate cannot tell you

Because the parent protein was identified in gastric juice, behaviour in an acidic medium is the first thing people ask about this molecule. It is a fair question to ask of the chemistry. It is not a question this page answers, and it is not a question any certificate answers either.

Stability in acid is a physicochemical property measured under stated conditions: a defined pH, a defined temperature, a defined time. A figure obtained in one medium does not transfer to another. Nothing on this page restates what any particular study reports, because a lot certificate measures purity, identity and net peptide content, and none of those is a stability figure. The literature's habit of building the word "stable" into the compound's own long name does not change that; it is a description from the source papers, not a released specification.

The same boundary applies to pharmacokinetics, and it is worth drawing explicitly because it is the most common category error in the subject. The 2025 narrative review in PubMed Central reports, from the animal work it cites, a plasma half-life of under thirty minutes with concentrations back to baseline within twenty-four hours. Take that figure or leave it: either way it is a measurement made in an organism, not a property of a vial. No release test on a lot of lyophilised powder produces it, no certificate states it, and a supplier who offered one would be telling you something the paperwork cannot support.

What does govern the material in front of a researcher is duller and more useful: temperature, moisture and time. The lyophilised cake is dry and stable at −20°C; once it has taken up water it is a solution with a finite life at 2 to 8°C. The general principles behind those two numbers are set out in how to store peptides, and they apply to the BPC-157 peptide the same way they apply to every other chain in the catalogue.

What the preclinical literature studies

Three areas account for most of the published work, and all three are model systems: tissue repair, gastrointestinal cytoprotection, and connective tissue. The endpoints within them are more specific than that summary suggests, and naming them is more useful than restating the summary.

The angiogenesis work reads out on vascular endothelial growth factor signalling and on new microvessel formation in injured-tissue and vascular-occlusion preparations in rodents. The connective-tissue work is largely in cultured tendon-derived fibroblasts, where migration rate in outgrowth and scratch assays is the primary measurement, and where a 2014 paper in Molecules examined growth hormone receptor expression in those same cultures by real-time PCR and Western blot. The gastrointestinal work, which follows directly from where the parent protein was found, uses rodent gastric and intestinal mucosal models including NSAID-challenge preparations, scored on mucosal lesions and epithelial barrier markers. Around the edges of all three sit the early-signalling readouts: Egr-1 transcription, FAK and paxillin phosphorylation, and nitric oxide pathway markers. Those are measurements of signalling rather than of outcomes.

Every one of those is preclinical: in-vitro systems and animal models, examined for signalling and for markers. None of it is a statement about a person, and nothing on this site is. The material is supplied for laboratory research use only, and the model systems above are described as models because that is what they are.

It is also worth saying what the literature does not yet contain, since the ranking pages on this term are not consistent about it. The published human record is thin. A Phase 2 trial in hamstring injury, NCT07437547, is listed on ClinicalTrials.gov as recruiting with no results posted, and the isolated safety reports in the literature are very small. An article that presents preclinical endpoints as settled outcomes is describing something other than the evidence.

Handling the BPC-157 peptide at the bench

The published cell work is a better guide to what this material is like to handle than any supplier page, because it states quantities. The 2014 tendon-fibroblast study worked at 0.1, 0.25 and 0.5 micrograms per millilitre in ordinary culture medium. Those are sub-microgram per millilitre concentrations, which puts a single 10mg vial at an enormous quantity of material on the scale the literature actually uses it.

Reconstitution is the ordinary business of a lyophilised peptide. The cake dissolves in bacteriostatic water and in 0.9% sodium chloride; the acidic, hydrophilic composition described above is why it goes into both readily rather than needing an organic co-solvent. Bacteriostatic water is the usual choice where a vial will be drawn from more than once, because the 0.9% benzyl alcohol in it suppresses bacterial growth between withdrawals. Bacteriostatic water for peptides sets out the difference against sterile water.

Storage is two numbers and a habit. Minus twenty for the sealed lyophilised vial, two to eight once it is in solution, and aliquoting rather than repeatedly warming and re-freezing one tube, because freeze-thaw cycles are the avoidable damage. One of the clinical pages on this search quotes a ten to fourteen day window for reconstituted material held refrigerated; that is a handling figure rather than a released specification, and it is a reasonable order of magnitude to plan around rather than a number any certificate here guarantees.

The cake itself is worth looking at before anything is added to it. A cake that has collapsed, gone glassy or shrunk away from the glass has been warm at some point in its history, and that is information the paperwork will not give you.

The BPC-157 peptide inside the GLOW and KLOW blends

The BPC-157 peptide appears in two multi-component vials in this catalogue, at 10mg in each, and a blend raises one documentation problem that a single-compound vial does not: a single purity figure for a vial containing three or four different molecules would be meaningless.

So the certificates report per component. A GLOW lot certificate states a measured content for the GHK-Cu, for the BPC-157 and for the thymosin beta-4 component separately, and a KLOW certificate does the same across its four. Across the four published GLOW lots the measured BPC-157 content runs from 9.84mg to 13.17mg against a 10mg label, and across the three published KLOW lots from 9.42mg to 10.57mg. Those are real measurements on real fills and the spread is what a real measurement of a multi-component fill looks like.

One naming detail is worth knowing before reading one of those documents. On several lots the certificate names the third component as Thymosin Beta-4, the full protein, rather than TB-500, its seven-residue fragment, and the catalogue lists it the way the certificate states it rather than the way the marketing convention would. GLOW vs KLOW goes through both formulations component by component.